Bartolome Moya Selected Research

zidebactam

1/2020	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa.
1/2019	In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.
1/2017	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bartolome Moya Research Topics

Disease

7	Infections 02/2024 - 01/2017
2	Cystic Fibrosis (Mucoviscidosis) 01/2019 - 10/2018
1	Persistent Infection 12/2019
1	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2019

Drug/Important Bio-Agent (IBA)

4	Anti-Bacterial Agents (Antibiotics)IBA 02/2024 - 01/2019
4	LactamsIBA 01/2020 - 01/2017
3	zidebactamIBA 01/2020 - 01/2017
2	cefepime-zidebactamIBA 01/2021 - 01/2020
2	WCK 5153IBA 01/2019 - 01/2017
1	Cefepime (Maxipime)FDA LinkGeneric 01/2020
1	QuinolonesIBA 10/2018

Therapy/Procedure

1	Therapeutics 12/2020